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Physiology of Sex Development
In sex development we can distinguish two different pro-
cesses: sex determination, which is the developmental deci-
sion that directs the undifferentiated embryo into a sexually
dimorphic individual, and sex differentiation, which takes
place once the sex determination decision has been made
through factors produced by the gonads that determine the
development of the phenotypic sex. At the beginning of
gestation (ﬁrst and second weeks), embryos of the two sexes
differ only in their karyotypes. Starting at week 3 speciﬁc
genes lead to the differentiation of the gonads that, in turn,
produce hormones inducing anatomical and psychological
differences, leading to behavioral differences that are ulti-
mately inﬂuenced by the social environment. At gestational
weeks 6 to 7 the paramesonephric duct (Müllerian duct)
develops next to the mesonephric duct (wolfﬁan duct). If
testes develop and secrete testosterone, the mesonephric
duct increases in size and differentiates into epididymis,
vas deferens, and prostate. A glycoprotein secreted from
the Sertoli cells, known as anti-Müllerian hormone or Mül-
lerian inhibiting substance, results in Müllerian duct regres-
sion. If testes do not develop, the mesonephric duct does not
grow and eventually degenerates, whereas the parameso-
nephric duct proliferates and the fallopian tube, uterus, and
upper third of the vagina develop.
In mammals, including humans, the differentiation of the
gonads is the turning point of thiswhole process. The classical
textbook theory says that in the presence of the sex-deter-
mining region on the Y-chromosome (SRY), the default female
pathway of sex determination will be inhibited and therefore
testes will be formed. In the XX individual because of the
absence of SRY no inhibition of the default program will take
place and ovaries will develop. Ovarian-determining factors
might help the process of differentiation. However, these
factors are not yet fully determined. The second model called
the Z-factor theory was proposed to explain the cases where
XX individuals develop testes in the absence of SRY. According
to this theory, the XX gonad expresses a factor that has both
antitestis and pro-ovary function. SRY in XY individuals acts
as an inhibitor of the Z-factor to lift the block on the male
pathway. In this case, the bipotential gonad will differentiate
into a testis.1
It seems that SRY acts on a single gene, SRY-box 9 (SOX9),
the expression of which is then rapidly reinforced by positive
The idea that the female sexual development happens by default was born in the middle
of the last century after Jost performed his innovative experiments to study the bases of
differentiation of the reproductive tract and found that the female reproductive tract
develops even in the absence of any gonad. The term default (passive) attributed to the
whole female developmental pathway, therefore, established itself, even if it was not
originally so intended. However, recent developments have demonstrated that ovarian
development is an active process. Wingless type MMTV integration site family, member
4 (WNT4), one of a few factors with a demonstrated function in the ovarian-determina-
tion pathway, has been found to be involved in sexual differentiation by suppressing
male sexual differentiation, promoting Müllerian duct differentiation, and maintaining
oocyte health. WNT4 expression in the ovary seems to be regulated by R-spondin 1
(RSPO1), a thrombospondin family member protein. The role and interactions of WNT4,
RSPO1, and other factors such as forkhead transcription factor 2 in ovarian development
and function will be discussed.
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regulatory loops. SOX9 then drives Sertoli cell formation and,
therefore, testis differentiation. If SRY is absent, fails to act in
time, or SOX9 is otherwise silenced, the follicle cell, chieﬂy
pregranulosa cells, develops and ovary ensues, with β-catenin
being one of the crucial components driving this process. In
simple terms testis formation requires SOX9 expression to be
high (on), while ovary development needs SOX9 to be low
(off) (►Fig. 1).
Although factors involved in male sexual differentiation
have been well studied, the pathways regulating female
sexual differentiation remain incompletely deﬁned. Until
recently, no genes had been identiﬁed to play a similar role
in ovarian development as was shown for SRYor SOX9 gene in
testicular development.Wingless typeMMTV integration site
family,member 4 (WNT4), R-spondin1 (RSPO1), and forkhead
transcription factor 2 (FOXL2) are some of the few factors
with a demonstrated function in the ovarian-determination
pathway. They suppressmale sexual differentiationmainly by
restraining SOX9 expression and promote female develop-
ment by sustaining Müllerian duct differentiation and oocyte
health (see below).
WNT4
WNT4 is a member of the WNT family of secreted molecules
that function in a paracrine manner to affect several devel-
opmental changes. WNT proteins bind to members of the
frizzled (FZ) family of cell-surface receptors and possibly to
the single-pass transmembrane protein LDL-receptor-related
proteins 5 and 6 (LRP5 and LRP6).2 The binding of WNT to FZ
leads to activation of the phosphoprotein dishevelled (DSH).
The activation and membrane recruitment of DSH probably
recruits and the destruction complex (including adenoma-
tous polyposis of the colon (APC), casein kinase 1, and
glycogen synthase kinase 3 [GSK3]) to the plasmamembrane,
where AXIN directly binds to the cytoplasmic tail of LRP5/6.
AXIN is then degraded, which decreases β-catenin degrada-
tion. The activation of DSH also leads to the inhibition of
GSK3, which further reduces phosphorylation and degrada-
tion of β-catenin with consequent β-catenin-dependent in-
duction of Wnt-responsive genes.3 Wnt proteins can also
signal via a β-catenin independent noncanonical pathway
involving protein kinase C and c-jun NH2-terminal kinase.4
(Readers interested in learning more about WNT proteins
should visit the informative site http://www.stanford.edu/
~rnusse/wntwindow.html.)
Wnt4 is produced in mouse ovarian somatic cells (pregra-
nulosa cells) and oocytes. In humans, WNT4 is expressed in
fetal granulosa cells at early stages with increasing expression
in oocytes in primordial follicles, with a peak at mid and late
gestation, when the follicles are formed.5 After birth, WNT4
expression was detectable in oocytes and granulosa cells,
especially in primary and secondary follicles, supporting the
idea that WNT4 is a “pro-ovary” factor. Wnt4 upregulates
dosage sensitive adrenal hypoplasia on chromosome X, gene 1
(Dax1),6 a gene known to antagonize the nuclear-receptor
steroid factor 1, and thereby inhibits steroidogenic enzymes.
Wnt4 collaborates with Rspo1 to stabilize β-catenin that, in
turn, works to limit the expression of the male-speciﬁc gene
Sox9, thus exerting an “antitestis” effect. Vainio et al7 observed
Figure 1 Somatic sex determination cascade based on studies in mice. The gonadal bipotential cells (green) into male Sertoli cells (blue) or
female pregranulosa cells (pink). The main players and their changes in gene expression driving supporting cell differentiation and the
downstream sexual differentiation of other gonadal cell types are indicated. Abbreviations: Rspo1, R-spondin 1; SRY, sex determining region Y;
Sox9, SRY-box 9; Wnt4, wingless-type MMMTV integration site family member 4. (Derived from Kocer A, Reichmann J, Best D, Adams IR. Germ cell
sex determination in mammals. Mol Hum Reprod 2009;15(4):205–213.62)
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in Wnt4-deﬁcient mice that gonadal development and ste-
roidogenic function were affected exclusively in femaleWnt4-
knockout mice, whereas both male and female mice had
similar defects in kidney development and adrenal function.
Wnt4-knockout female mice were masculinized, as demon-
strated by the absence of Müllerian ducts and the presence of
wolfﬁan ducts, and expressed the steroidogenic enzymes 3β-
hydroxysteroid dehydrogenase and 17α-hydroxylase, which
are required for the production of testosterone and are nor-
mally suppressed in the developing female ovary. Further-
more, female mice lackingWnt4 and follicostatin have in their
gonads a testis-speciﬁc artery, the coelomic vessel,which plays
a critical role in patterning of testis cords and later in hormone
transport.8 On the other hand, the ovaries of the Wnt4-
knockout mice also had less oocytes, suggesting a role of
Wnt4 in the life of female germ cells. This function is crucial
for the organization of ovarian structure, because female germ
cells have a central role in this process and in maintenance of
the ovary, as demonstrated by the fact that when oocytes are
either absent9 or lost after follicle formation10 ovarian follicles
never form or degenerate subsequently. In contrast, testis
development proceeds in the absence of germ cells. WNT4
appears to maintain oocyte viability once germ cells have
reached their ﬁnal destination in the gonad.
Naillat et al11 demonstrated in mice that somatic Wnt
signaling was crucial for the control of female germ line
development. Wnt4 maintained germ cell cysts and early
follicular gene expression and provided a female pattern of E-
cadherin and β-catenin expression within the germ cells.
Reintroduction of a Wnt4 signal to the partially masculinized
embryonic ovary rescued the female property to a certain
degree.Wnt4 deﬁciency allowed only 20% of the germ cells to
initiate meiosis in the ovary.
Ottolenghi et al12 observed formation of testis-like tubules
and spermatogonia in the ovaries of Wnt4/Foxl2 double-
knockout XX mice, demonstrating that female sex-determin-
ing genes, the putative “ovary organizer,” are required to
suppress an alternative male fate in the ovary and act as a
female equivalent of SRY.
WNT4 and Human Disease
In humans more copies of WNT4, because of duplication of
chromosome 1p31-p35, were found in a patient with ambig-
uous genitalia, severe hypospadia, ﬁbrous gonads, and rem-
nants of both Müllerian and wolfﬁan ducts, that is, male-to-
female sex reversal.5 On the other end of the spectrum, when
both copies of the gene are inactive, as in the case of
homozygote mutations, a severe clinical entity called the
SERKAL syndrome results.13 The syndrome was described
in three 46, XX fetuses and is characterized by female-to-male
sex reversal with ambiguous genitalia, gonadal morphology
ranging from ovotestis to normal testis, renal agenesis, adre-
nal hypoplasia, and pulmonary and cardiac abnormalities. In
the middle of such spectrum one might expect to ﬁnd
patients with intermediate defects of sex development.
Searches for clinically relevant WNT4 mutations sometimes
in large cohorts of these patients were unsuccessful.14 We
described awomanwith absentMüllerian structures (uterine
and fallopian tubes) who had unilateral renal agenesis and
clinical signs of androgen excess. Her phenotype resembles
that of patients with the Mayer–Rokitansky–Küster–Hauser
syndrome and is also strikingly similar to that of Wnt4-
knockout female mice (►Fig. 2A, B). This constellation of
ﬁndings prompted us to search for mutations in the WNT4
gene in this patient. Direct sequencing of polymerase chain
reaction-ampliﬁed exonic fragments revealed a heterozygous
mutation leading to an E226G/WT missense exchange in the
WNT4 protein. In search for causes of the defective signaling,
we found that the E226G mutant protein appears to be
trapped inside the cell,15 likely because of defective post-
translational lipid modiﬁcation, necessary for WNT proper
function.3 Because any generalizations regarding WNT4 role
in humansmust await the description and characterization of
mutations in additional patients, we searched for additional
subjects with WNT4 mutations. The recent identiﬁcation of
other women16–18with a similar phenotype andmutations in
WNT4 conﬁrmed its role in ovarian and female reproductive
tract development in women (►Fig. 2C). These additional
patients also helped to reﬁne the phenotype of WNT4 deﬁ-
ciency in humans. In fact, it appears that the absence of uterus
(and not other Müllerian abnormalities) and the androgen
excess are the pathognomic signs of WNT4 defects, suggest-
ing that this might be a clinical entity distinct from the
classical Mayer–Rokitansky–Küster–Hauser syndrome. The
functional studies performed in these cases suggested that
the consequences of the present WNT4 mutation range from
lack of lipid modiﬁcation (and probable misfolding),15 to
misfolding and formation of intractable aggregates,16 to
defects in receptor binding17,18 (►Fig. 2C). The fact that these
patients are heterozygotes and the results of the expression
studies suggest that one normal copy of WNT4 is not only
inadequate tomaintain protein function but is also negatively
inﬂuenced by the mutant protein (dominant negative effect).
Although this is not a classical gene-dosage phenomenon,
because the gene copies are the same (except in the duplica-
tion case), it is certainly a dosage-sensitive sex-determining
process, as Jordan et al already predicted.5 In fact, while too
much WNT4 activity (duplication) induces feminization of
the male (46, XY disorders of sex development [DSD]), too
little WNT4 activity (homozygous loss-of-function mutation)
induces exactly the opposite; i.e., masculinization of the
female (46, XX DSD). Because WNT4 inhibits the male devel-
opment in the female and males do not need WNT4 for their
sex development,6 situations between these two extremes
are characterized by different degrees of masculinization of
the female. Although the presence of negative dominance
renders the case arithmetically more complex, the relation-
ship between activity levels and phenotype of WNT4 abnor-
malities is rather striking and corroborates the idea that sex
differentiation is a matter of dosage (►Fig. 3).
RSPO1
Kamata et al19 identiﬁed the mouse Rspo1 gene, which
encodes a 265 amino acid sequence with a calculated molec-
ular mass of 29 kD. Unlike other secretory proteins of the
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thrombospondin family, RSPO contains no apparent secretion
cleavage site, but has a putative N-terminal nuclear localiza-
tion signal. RSPO transcripts were observed mainly in central
nervous system (CNS) tissues. Outside the , RSPO transcripts
were detected in forelimb buds after 10 days post conception,
especially in the body trunk and the proximal posterior part
of the anterior limb bud. Kim et al found that human RSPO is
expressed in enteroendocrine cells aswell as in epithelial cells
from various tissues.20
In mice, the ovarian phenotype of XX, Rspo1 / is
strikingly similar to that ofWnt4 / female mice, especially
for the formation of coelomic vessels and the presence of
functional steroidogenic cells. These animal models suggest
that the ovarian phenotype in Rspo1 / mice is at least in
part because of failing overexpression of Wnt4 in XX gonads.
In contrast, Rspo1 / female mice do not show adrenal or
uterine abnormalities, as Wnt4 /mice do, in agreement to
the fact that Rspo1 is not expressed in adrenals or mesoneph-
ros, indicating that activation of Wnt4 in these organs is
independent of Rspo1 (for review see Chassot et al (2008)21).
Several lines of evidence demonstrated that RSPO1 syner-
gizes with WNT4 in XX gonads to stabilize β-catenin.22 The
comparison of the phenotypes of mice lacking RSPO1 or
WNT4 suggests that the RSPO1 regulates and synergizes
with WNT4 in the developing gonad, but not in the internal
genitalia anlagen or the adrenals (►Table 1).
RSPO-1 and Human Disease
The essential role of RSPO1 in human ovarian development
was demonstrated by studying individuals with palmoplan-
tar hyperkeratosis with squamous cell carcinoma of skin and
46XX, DSD in whom Parma et al demonstrated mutations in
the RSPO1 gene.23 The authors concluded that RSPO1 is
produced and secreted by ﬁbroblasts and regulates keratino-
cyte proliferation and differentiation. The presence of “func-
tional” testes in the sex-reversed individuals was conﬁrmed
by the absence of Müllerian derivatives and by the masculin-
ization of the internal and external genitalia, presumably
induced by functioning Sertoli and Leydig cells, respectively.
All sex-reversed individuals were sterile. Notably, the normal
reproductive phenotype of 46, XY individuals suggested that
normal RSPO1 is not required for testis differentiation and
function.
Figure 2 (A) Magnetic resonance imaging of the abdominal cavity of the ﬁrst WNT4-deﬁcient patient showing lack of uterus and tubes, the renal
agenesis, and the ectopic ovary. For comparison, the correspondent structure of wild type (Wnt4 þ/þ) and female mice lacking Wnt4 (Wnt4/)
are depicted in panel (B) (from Vainio S, Heikkilä M, Kispert A, Chin N, McMahon AP. Female development in mammals is regulated by
Wnt-4 signalling. Nature 1999;397(6718):405–409.6) (C) Knownmutations inWNT4 gene found in women with no uterus and signs of virilization.
The functional consequences of the mutations are also reported. Homozygote mutations (not shown) are linked to a more severe entity,
called SERKAL syndrome.13
Figure 3 Hypothetical relationship between WNT4 dosage and
manifestation of disease. Normal function (and dosage) is set as 1.0.
Heterozygote mutations have a dominant negative effect on the wild-
type protein (red line) and lower the activity by 20% instead of the
expected 50%.
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In a 46, XX SRY-negative woman with true hermaphrodit-
ism and palmoplantar keratoderma whose parents were ﬁrst
cousins, in whom no mutations were found in several other
gene, including WNT4, Tomaselli et al24 identiﬁed homozy-
gosity for a splice site mutation in the RSPO1 gene. The
authors stated that this was the ﬁrst patient in whom XX
true hermaphroditism was associated with a single gene
alteration in the absence of SRY.
FOXL2
FOXL2 is a single-exon gene encoding a forkhead/winged
helix transcription factor and a nuclear protein.25 In verte-
brates, FOXL2 is one of the earliest knownmarkers of ovarian
differentiation.26 Thus, it may play a role in the early stage of
development of the ovarian somatic compartment. As it is still
strongly expressed in postnatal and adult follicular cells, it is
thought to play a role in follicle development and/or mainte-
nance during fertile life.
Despite the importance of FOXL2 in ovarian development
and maintenance, only a few transcriptional targets have
been described so far.27,28 FOXL2 seems to stimulate the
expression of the gonadotropin-releasing hormone receptor.
Foxl2 expression precedes glycoprotein hormone α-subunit
(α-GSU; common subunit to FSH, LH, and TSH) expression in
the pituitary, suggesting that the α-GSU gene is a downstream
target of FOXL2. Indeed, it has been shown that expression of
Foxl2 activates the expression of α-GSU in cellular and
transgenic mice models by a direct effect on the α-GSU
promoter.29 Some data suggest that target speciﬁcity could
stem from the interactions of Foxl2 with still unknown
cofactors expressed in a tissue and/or cell speciﬁc manner.30
FOXL2 has also been shown to interact directly with the
promoter of the steroidogenesis acute response (StAR) gene,
to induce a robust inhibition of its basal transcriptional
activity.27 StAR is a marker of late differentiation of granulosa
cells in preovulating follicles and catalyzes cholesterol trans-
location from the outer to the inner mitochondrial mem-
brane, where it can subsequently be processed in its way to
yield pregnenolone and eventually steroid hormones. This
translocation of cholesterol is the rate-limiting step in ste-
roidogenesis. The role of FoxL2 in steroidogenesis in the ovary
was further strengthened by the fact that it can upregulate
the expression of aromatase, the enzyme responsible for the
transformation of androgens to estrogens in granulosa cells.28
In addition, FOXL2 seems to play a role in the reactive
oxygen species detoxiﬁcation pathways, as several of its
members are upregulated by the overexpression of FOXL2,
namely peroxisome proliferator-activated receptor gamma
coactivator 1-alpha, immediate early response 3, and the
mitochondrial manganese superoxide dismutase genes
(Moumné L et al (2008) and references therein).31 It is known
that an increased resistance to oxidative stress correlateswith
longevity.32 Thus, FOXL2 could play a major role in the
regulation of ovarian senescence because its mutation leads
to a phenotype similar to an accelerated ovarian aging (see
below). FOXL2 also appears to be implicated in the regulation
of apoptosis, as it activates the transcription of several genes
encoding factors involved in apoptotic processes.33 In addi-
tion, FOXL2 seems to regulate players of inﬂammation pro-
cesses such as several chemokine ligands and especially
prostaglandin-endoperoxide synthase 2 (PTGS2)/ cyclooxy-
genase 2. The latter is one of the two isoforms of cyclo-
oxygenases involved in the synthesis of prostaglandins and
catalyses the rate-limiting step of conversion of arachidonic
acid into prostaglandin H2, which is subsequently converted
to other prostaglandins by speciﬁc synthases.34 The fact that
FOXL2 strongly activates PTGS2 points to an important role
for prostaglandins in ovarian function and lead to the claims
that ovulation is an inﬂammatory-like process and suggests
that FOXL2 might act very early during gonadal determina-
tion and all the way through the latest stages of follicular
maturation and ovulation.
The crucial role of FOXL2 in the life of the ovary has been
supported by the seminal work of Uhlenhaut et al,35 who by
deleting Foxl2 in adult mice ovary, reprogrammed granulosa
and theca cells into Sertoli- and Leydig-like cells. This work
elegantly shows that the mammalian ovarian phenotype has
to be maintained throughout life, mainly by active repression
of the male-promoting gene Sox9.
Table 1 Reproductive Phenotype in 46,XX Knock-Out Mice
Wnt4 Rspo1 Possible Mechanism
Coelomic vessels no no Failed Wnt4 up-regulation
Leydig-like cells
(Androgen-synthesis
enzymes expression)
yes yes Failed Wnt4 up-regulation
Sertoli-like cells (Sox9 and
Amh expression)
yes yes Failed Wnt4 up-regulation
Germ cells Many survive after birth,
but only 20% enter meiosis
Only 10% survive Normal basal (non stimulated)
Wnt4 expression in Rspo1 -/-
Internal genitalia No Müllerian deriatives Hermaphodite Wnt4 is expressed in the
mesonephron, Rspo1 is not
Adrenals Ectopic vessels Normal Wnt4 is expressed in adrenals, Rspo1 is not
Derived from references.21,64
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FOXL2 and Human Disease
Mutations in FOXL2 are responsible for blepharophimosis–
ptosis–epicanthus inversus syndrome (BPES), which is a
genetic disease leading to complex eyelid malformation and
other mild craniofacial abnormalities and can present itself
with premature ovarian failure (POF) (i.e., BPES I) or without it
(BPES II).
In addition, work by Shah et al36 analyzed four adult-type
ovarian granulosa-cell tumor (GCT) specimens for GCT-
speciﬁc mutations and identiﬁed a somatic point mutation,
(C134W) in the FOXL2 gene in all four specimens. The C134W
mutation was present in several other additional GCTs and
thecomas, but was absent in sex cord/stromal tumors of other
types and unrelated ovarian or breast tumors. The authors
concluded that mutant FOXL2 is a potential driver in the
pathogenesis of adult-type GCTs.
In search for a molecular mechanism and a genotype–
phenotype correlation, Moumné et al37 showed that prema-
ture stop codons in the FOXL2 gene may lead to the produc-
tion of N-terminally truncated proteins that strongly
aggregated in the nucleus, partially localized in the cyto-
plasm, and retained a fraction of the wild-type protein. The
same authors in amore recent study38 noted that polyalanine
expansions of þ10 residues (i.e., 24 alanines) in FOXL2 have
been identiﬁed in 30% of BPES patients and are mainly
responsible for BPES type II. Dipietromaria et al39 dissected
the molecular and functional effects of 10 FOXL2 mutants,
known to induce BPES with or without POF. There was a
correlation between the transcriptional activities of FOXL2
variants, suggesting that a FOXL2 mutant completely lacking
transactivation activity is likely to lead to BPES with POF.
More recently, Benayoun et al40 by using a functional geno-
mic approach found that FOXL2 modulates cell-cycle regu-
lators in a way that tends to induce G1 arrest and protects
cells from oxidative damage. They also demonstrated in
agreement with clinical observations that FOXL2 mutants
found in BPESwith ovarian dysfunction (BPES I) mostly fail to
transactivate cell-cycle and DNA-repair targets, whereas
mutations leading to isolated craniofacial defects (and nor-
mal ovarian function, BPES II) activate them correctly. Sirtuin
1 deacetylase appears to play a key role in this process by
suppressing FOXL2 activity on targets linked to cell-cycle and
DNA repair in a dose-dependent manner. This evidence
supports the idea that FOXL2 plays a key role in granulosa
cell homeostasis, the failure of which is central to ovarian
aging and tumorigenesis.
Additional Factors
These factors, although not directly involved in ovarian
determination, are essential for ovarian function and survival.
Two oocyte-speciﬁc transcription factors, among others,
also play a critical role in oocyte survival: factor in the
germline α41 and newborn ovary homeoBOX-encoding
gene (NOBOX).42 Absence of these genes results in oocyte
death and prevents the subsequent formation of primordial
follicles because of a failure of the ovigerous cords to become
follicles.43 Fbxw15/Fbxo12J, an F-box containing gene speciﬁ-
cally expressed in mouse ovary, was recently shown to
possibly contribute to ovarian physiology by preventing
oocytes from exiting meiotic prophase or by regulating
signaling events required for oocyte-granulosa cell commu-
nication.44 Bone morphogenic protein 15 (BMP15) and
growth differentiation factor 9 (GDF9) are crucial for ovari-
an follicle physiology, probably by controlling its metabo-
lism.45 In women, BMP15 and NOBOX mutations have
Figure 4 Simpliﬁed view of the ovarian germ cell/follicle develop-
mental cascade and the sequence of factors regulating the process.
Abbreviations: Cited2, Cbp/P300-Interacting Transactivator 263; SF-1,
steroidogenic factor 1; Wnt4, wingless-type MMMTV integration site
family member 4; RSPO1, R-spondin 1; FOXL2, Forkhead transcription
factor; Figα, Factor in Germline α; NOBOX, Newborn Ovary.
Figure 5 Simpliﬁed model of sex development cascade. In early
stages of determination, SRY in XY subjects initiates SOX9 upregula-
tion, which is then maintained by SOX9 itself, SF1, PTGD2, and FGF9. In
the XX gonad WNT4/RSPO1 stabilize β-catenin that, in turn, sup-
presses SOX9. After birth, FOXL2 with the help of the ERs maintains the
transcriptional repression of SOX9, which is necessary to preserve
ovarian function throughout life. Abbreviations: ERs, estrogen recep-
tors; FOXL2, forkhead transcription factor; FGF9, ﬁbroblast growth
factor 9; PTGD2, prostaglandin D2; RSPO1, R-spondin 1; SF1, ste-
roidogenic factor 1; SOX9, SRY-box 9; WNT4, wingless-type MMMTV
integration site family member 4.

ht
tp
://
do
c.
re
ro
.c
h
been associated with POF,46–48 whereas GDF9 aberrant
expression and genomic variants have been linked to pre-
mature ovarian insufﬁciency and twin pregnancy, respec-
tively.49–52 Maintenance of follicle “identity” is guaranteed
by estrogen formation and action, as demonstrated by the
transdifferentiation of normally formed ovarian tissue into
testicular structures in mice lacking enzyme aromatase
(converting androgens to estrogens)53 and/or estrogen re-
ceptor.54,55 Human steroidogenic factor-1 (SF1/NR5A1) is a
461 amino acid protein that shares structural homology
with other members of the nuclear receptor superfamily
essential for the developing adrenals and male gonad. In 46,
XY individuals, mutation in the human SF1/NR5A1 gene has
a phenotypic spectrum that ranges from complete testicular
dysgenesis with Müllerian structures, through individuals
with mild clitoromegaly or genital ambiguity, to severe
penoscrotal hypospadias or even anorchia.56 In females,
persistent expression of SF1 has been reported in early
ovarian development in humans,57 whereas SF1 expression
may decline in the mouse. However, SF1 is detectable in
somatic cells (granulosa and theca cells) of the adult ova-
ry.58 Although SF1 is not required for ovarian determina-
tion,59 heterozygote mutations in NR5A1 have recently been
linked to ovarian insufﬁciency.60
Conclusions
The idea that the female sexual development is passive and
happens by default was based on the fact that the female
reproductive tract develops even in the absence of any gonad.
Recent advances demonstrated that ovarian development
and maintenance are active processes. In fact, WNT4 syner-
gizes with RSPO1 to stabilize β-catenin that, in turn, sup-
presses expression of the male-speciﬁc gene SOX9.35 As a
consequence migration of mesonephric endothelial and ste-
roidogenic cells, formation of male-speciﬁc coelomic blood
vessels and production of steroids are prevented,7,61with an
overall “antitestis” effect. WNT4, RSPO1, and FOXL2 also
work as “pro-ovary” factors, with WNT4/RSPO1 being nec-
essary for early somatic cell differentiation and for protection
of the germ cells in mice6 and in humans,17 while FOXL2 is
essential for follicle formation and identity21 (►Fig. 4). These
factors work in concert but at different time points: during
determination in utero, the process is led by the WNT4/
RSPO1/β-catenin pathway; after birth and throughout life,
FOXL2 (and the estrogen receptors) are the major regulators.
Thus, it appears that while male sex determination is regu-
lated by a single pathway of SOX9 activation, the female
ovarian development is controlled by at least two ways of
SOX9 suppression (►Fig. 5).
From a more clinical point of view, mutations in these
factors have consequences not only for ovarian ontogeny and
sex development but their interactions are necessary
throughout the lifetime of the female to prevent ovarian
dysfunction, including infertility, premature ovarian insufﬁ-
ciency, and perhaps polycystic ovary syndrome (►Fig. 6).
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